report_lead_image_with_gradient.png
Q2 2025

Medtech Public Comp Sheet and Valuation Guide

Download this Report
To download this report, please complete the form below

Fill out the form to download a preview of this report. The full Excel data pack is available through the PitchBook Platform.

Tempus, Grail drive medtech stock rally in 2025

Medtech outperformed the broader market for the second straight quarter, with every subsector delivering median double-digit gains—well ahead of the S&P 500’s 9.7% rise. Leading the rally were Tempus AI and Exact Sciences, each posting share price jumps of nearly 60% as investor appetite for high-growth diagnostics returned in force.

The IPO window, long dormant in medtech, may be stirring. Caris Life Sciences made headlines with a $7 billion listing in June, raising nearly $500 million—one of the sector’s largest debuts in recent years. While continued macroeconomic uncertainty and flat growth projections may temper enthusiasm, recent IPO successes and a rotation into higher-risk diagnostics point to potential for renewed momentum should favorable sector dynamics emerge.

Our Q2 2025 Medtech Public Comp Sheet and Valuation Guide tracks metrics for key publicly traded companies that include stock performance, changes in valuation, historical valuations, revenue growth, EBITDA growth, and EBITDA margins. It is constructed using the PitchBook Excel plugin available to subscribers.


Table of contents
Key takeaways 2
Stock returns 3
Valuations 4
Revenue 5
EBITDA 6